ストックスクリーナーアプリを入手
21.96
0.23%
-0.06
前日終値:
$22.02
開ける：
$22.02
24時間の取引高:
567.40K
Relative Volume:
0.35
時価総額：
$3.75B
収益：
$1.07B
当期純損益:
$391.00M
株価収益率:
9.5962
EPS:
2.2884
ネットキャッシュフロー:
$6.31M
1週間 パフォーマンス:
-2.62%
1か月 パフォーマンス:
+6.60%
6か月 パフォーマンス:
+1.06%
1年 パフォーマンス:
+46.56%
1日の値動き範囲:
$21.77
$22.32
1週間の範囲:
$20.96
$22.66
52週間の値動き範囲:
$14.08
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
名前
Acadia Pharmaceuticals Inc
セクター
電話
858-558-2871
住所
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
21.97 | 3.75B | 1.07B | 391.00M | 6.31M | 2.2884 |
VRTX
Vertex Pharmaceuticals Inc
|
442.76 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.47 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
842.22 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
335.30 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
317.07 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-02-23 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-10-21 | 開始されました | Citigroup | Buy |
| 2025-05-21 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2025-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 開始されました | BMO Capital Markets | Outperform |
| 2024-03-12 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-03-12 | 繰り返されました | Needham | Buy |
| 2024-01-30 | 開始されました | Robert W. Baird | Outperform |
| 2024-01-24 | アップグレード | Needham | Hold → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-06 | アップグレード | Mizuho | Neutral → Buy |
| 2023-10-17 | 開始されました | UBS | Buy |
| 2023-10-10 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-01-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-11-04 | ダウングレード | Goldman | Neutral → Sell |
| 2022-11-01 | 開始されました | Loop Capital | Hold |
| 2022-08-08 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-05 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-06-21 | ダウングレード | Jefferies | Buy → Underperform |
| 2022-06-16 | アップグレード | Jefferies | Hold → Buy |
| 2022-03-16 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | アップグレード | Citigroup | Neutral → Buy |
| 2021-12-21 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-06-10 | 開始されました | Berenberg | Hold |
| 2021-04-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | ダウングレード | Goldman | Buy → Neutral |
| 2021-04-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-04-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-05 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-03-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-03-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-03-09 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2020-12-16 | 開始されました | Mizuho | Buy |
| 2020-11-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-07 | アップグレード | Stifel | Hold → Buy |
| 2020-04-16 | 開始されました | Jefferies | Buy |
| 2020-03-31 | アップグレード | Goldman | Neutral → Buy |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2019-12-16 | 開始されました | Guggenheim | Buy |
| 2019-10-24 | 開始されました | Oppenheimer | Perform |
| 2019-10-01 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-09-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 繰り返されました | Needham | Buy |
| 2018-12-10 | 開始されました | Canaccord Genuity | Hold |
| 2018-09-21 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 繰り返されました | Stifel | Hold |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-08-06 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
すべてを表示
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
ACADIA Pharmaceuticals stock (US0042251084): Is the next product pipeline now the real test for sust - AD HOC NEWS
Acadia launches powder version of Rett syndrome treatment in the US - MSN
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical - Yahoo
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Does ACADIA Pharmaceuticals Inc stock reflect fundamentals2026 Chart Watch & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Breakout Watch: What is the target price for ACADIA Pharmaceuticals Inc stockWeekly Profit Recap & Technical Pattern Based Signals - baoquankhu1.vn
ACADIA Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - Yahoo Finance Singapore
ACADIA Pharmaceuticals Insider Sells Over $22,000 in Stock - National Today
ACAD Stock Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Neuren Pharmaceuticals advances Rett syndrome treatment with US launch of DAYBUE STIX - BioMelbourne Network
Sectors Review: Is ACADIA Pharmaceuticals Inc being accumulated by smart money2026 Biggest Moves & AI Driven Price Forecasts - baoquankhu1.vn
(ACAD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Acadia Pharma EVP Schneyer sells $60k in stock By Investing.com - Investing.com Australia
Acadia Pharmaceuticals officer sells $22,866 in stock By Investing.com - Investing.com Australia
Acadia Pharmaceuticals officer sells $22,866 in stock - Investing.com
Acadia Pharma EVP Schneyer sells $60k in stock - Investing.com
[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Acadia (NASDAQ: ACAD) officer sells shares to cover RSU tax obligations - Stock Titan
Acadia Pharmaceuticals Launches DAYBUE STIX for Rett Syndrome - National Today
Acadia Pharmaceuticals (ACAD) Expands Access to Rett Syndrome Tr - GuruFocus
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome - Bakersfield.com
User - The Chronicle-Journal
RBC Capital Adjusts ACADIA Pharmaceuticals PT to $29 From $30, Maintains Outperform Rating - Moomoo
ACADIA Pharmaceuticals Inc. (ACAD.MX) Income Statement - Yahoo! Finance Canada
Advantage Alpha Capital Partners LP's ACADIA Pharmaceuticals Inc(ACAD) Holding History - GuruFocus
IPO Launch: Is ACADIA Pharmaceuticals Inc being accumulated by smart money2026 Growth vs Value & Technical Confirmation Alerts - baoquankhu1.vn
ACADIA Pharmaceuticals Inc. $ACAD Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Trade Near Recent Levels - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
ACAD PE Ratio & Valuation, Is ACAD Overvalued - Intellectia AI
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Relay Therapeutics, Inc. Stock? - AAII
Insiders At ACADIA Pharmaceuticals Sold US$1.0m In Stock, Alluding To Potential Weakness - 富途牛牛
ACADIA Pharmaceuticals Inc (DR6.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Glioblastoma Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics, Autotelic Therapeuti - Barchart
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN
Layoff Watch: Is ACADIA Pharmaceuticals Inc being accumulated by smart moneyStop Loss & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Update Recap: Can ACADIA Pharmaceuticals Inc continue delivering strong returns - baoquankhu1.vn
Acadia Pharmaceuticals stock drops 3.35% as company gears up for post-acute care conference - Traders Union
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Mixed Share Performance - simplywall.st
Acadia Pharma EVP Schneyer sells $159k in stock By Investing.com - Investing.com Australia
Acadia Pharma EVP Schneyer sells $159k in stock - Investing.com UK
Acadia Pharmaceuticals exec sells $41,895 in stock By Investing.com - Investing.com India
Acadia Pharmaceuticals exec sells $41,895 in stock - Investing.com
Acadia EVP Thompson sells $73k in stock after option exercise - Investing.com
Acadia EVP Rhodes sells $82k in stock after option exercise - Investing.com
Acadia Pharma CEO Owen Adams Catherine sells $249k in stock - Investing.com
Acadia Pharma CEO Owen Adams Catherine sells $249k in stock By Investing.com - Investing.com India
Acadia EVP Rhodes sells $82k in stock after option exercise By Investing.com - Investing.com South Africa
ACADIA (NASDAQ: ACAD) officer sells 1,942 shares after RSU vesting - Stock Titan
Acadia Pharmaceuticals Inc (ACAD) 財務データ
収益
当期純利益
現金流量
EPS
Acadia Pharmaceuticals Inc (ACAD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
Apr 07 '26 |
Sale |
22.20 |
1,030 |
22,866 |
27,865 |
| Owen Adams Catherine | Chief Executive Officer |
Mar 24 '26 |
Option Exercise |
0.00 |
23,509 |
0 |
26,444 |
| Owen Adams Catherine | Chief Executive Officer |
Mar 25 '26 |
Sale |
21.47 |
11,641 |
249,932 |
14,803 |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC |
Mar 24 '26 |
Option Exercise |
0.00 |
7,515 |
0 |
15,124 |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC |
Mar 25 '26 |
Sale |
21.47 |
3,844 |
82,531 |
11,280 |
| Thompson Elizabeth H.Z. | EVP, Head of Research & Dev |
Mar 25 '26 |
Sale |
21.47 |
3,435 |
73,749 |
3,280 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
Mar 26 '26 |
Sale |
21.65 |
1,109 |
24,011 |
26,885 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
Mar 25 '26 |
Sale |
21.47 |
833 |
17,885 |
25,852 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Mar 25 '26 |
Sale |
21.47 |
4,177 |
89,680 |
57,299 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Mar 26 '26 |
Sale |
21.65 |
3,208 |
69,456 |
60,269 |
2.68%
0.34%
大文字化:
|
ボリューム (24 時間):